|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.
|
22071890 |
2012 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, deregulation of ALK tyrosine kinase activity is critical for the pathogenesis of several other pediatric tumors, including neuroblastomas and inflammatory myofibroblastic tumors.
|
23696342 |
2013 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Treatment of neuroblastoma cells with MY10 or MY33-3 also increased levels of phosphorylated ALK and TrkA.
|
29753117 |
2018 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the ALK mutation was somewhat lower than that expected in Korean patients with NBs.
|
21940108 |
2011 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
However, we delineated a reduced sensitivity of ALK mutated NB cells to entrectinib, and demonstrated strong activation of autophagy in SH-SY5YF1174L NB cell line.
|
26735175 |
2016 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment.
|
30538293 |
2019 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Focal aberrations affect genes known to be involved in neuroblastoma, such as ALK and LIN28B.
|
30375995 |
2018 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Point mutations and amplification of the ALK gene occur in the childhood cancer neuroblastoma.
|
20451371 |
2010 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
ALK copy number changes and amplification, which plays an oncogenic role in tumors such as neuroblastoma, are poorly characterized in NSCLC.
|
21107285 |
2011 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we evaluated the ALK mutational status of NB samples by analysis of circulating DNA, using the droplet digital PCR (ddPCR) system. ddPCR assays was developed for the detection of ALK mutations at F1174 and R1275 hotspots found in NB tumors and was applied for the analysis of circulating DNA obtained from 200 μL of serum or plasma samples collected from 114 patients with NB.
|
25653133 |
2015 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Parallel pre-clinical studies are demonstrating the efficacy of ALK inhibitors against common ALK variants in NB; however, a complex picture of therapeutic resistance is emerging.
|
29642598 |
2018 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 1-2% of neuroblastomas are inherited in an autosomal dominant fashion and a combination of co-morbidity and linkage studies has led to the identification of germline mutations in PHOX2B and ALK as the major genetic contributors to this familial neuroblastoma subset.
|
29589100 |
2018 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A recently approved small-molecule inhibitor of ALK has shown promising preclinical activity for neuroblastoma and is currently in phase I and II trials.
|
22589483 |
2012 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Collectively, our IPP analysis provides insight into the proximal architecture of oncogenic ALK signaling by revealing IRS2 as an adaptor protein that links ALK to neuroblastoma cell survival through the Akt-FoxO3 signaling axis.
|
30459283 |
2018 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have analyzed tyrosine kinase domain mutations and amplification/expression of the ALK gene and focused on clinical features of neuroblastoma cases with ALK aberrations.
|
23084186 |
2012 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase (ALK) has been validated to play important roles in various cancers, especially anaplastic large cell lymphoma (ALCL), nonsmall cell lung cancer (NSCLC), and neuroblastomas.
|
31419130 |
2019 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
It is now also appreciated that the full-length ALK receptor can be activated by point mutations and by deletions within the extracellular domain, such as those observed in neuroblastoma.
|
23889739 |
2013 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activating mutations in full length anaplastic lymphoma kinase (ALK) have been reported in neuroblastoma and in anaplastic thyroid cancer.
|
28030793 |
2017 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the presence of ALK<sup>F1174L</sup> signaling, MYCN induces the expression of the ubiquitin ligase SKP2 (S-phase kinase-associated protein 2), which targets p27 for degradation and is also upregulated in high-risk NB.
|
27707976 |
2016 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.
|
29660984 |
2018 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Regarding the latter, although it has been shown that Notch2 functions as a receptor in neuroblastoma cells, it is likely that other receptors (e.g. anaplastic lymphoma kinase) are also involved in midkine signalling.
|
24116381 |
2014 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results suggest that alectinib is an effective inhibitor of ALK kinase activity in ALK addicted neuroblastoma and should be considered as a potential future therapeutic option for ALK-positive neuroblastoma patients alone or in combination with other treatments.
|
31334113 |
2019 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Intrinsic susceptibility-MRI could thus potentially provide a non-invasive and clinically-exploitable method to help identifying children with MYCN-driven neuroblastoma harboring the ALK(F1174L) mutation at the time of diagnosis.
|
24667968 |
2014 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.
|
28546523 |
2018 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that D5F3 immunohistochemistry, single-color CISH and IT-PGM sequencing are suitable assays for evaluation of ALK status in future neuroblastoma clinical trials.
|
25188507 |
2014 |